Ignite Creation Date:
2025-12-25 @ 2:10 AM
Ignite Modification Date:
2025-12-29 @ 2:20 AM
Study NCT ID:
NCT06384560
Status:
RECRUITING
Last Update Posted:
2025-01-20
First Post:
2024-04-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)
Sponsor:
Amsterdam UMC, location VUmc
Organization:
Study Overview
Official Title:
Neoadjuvant Triple Treatment with FOLFIRINOX Plus Pembrolizumab and SABR in Patients with Borderline Resectable Pancreatic Cancer (PREOPANC-5): a Multicenter Single Arm Phase I/II Trial of the Dutch Pancreatic Cancer Group
Status:
RECRUITING
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PREOPANC-5
Brief Summary:
Since patients with borderline resectable pancreatic cancer (BRPC) have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment chemotherapy, immunotherapy and radiotherapy, followed by surgery and chemotherapy and immunotherapy survival in patients with BRPC.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: